Table 1. Covariates and outcomes.
| Covariate | Group | CND (+) N (%) | CND (−) N (%) | OR (95% CI) | P value | DCI (+) N (%) | DCI (−) N (%) | OR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|---|
| Race | Non-Caucasian | 21 (11.5) | 15 (10.1) | 1.16 (0.57–2.33) | 0.681 | 16 (12.9) | 20 (9.6) | 1.40 (0.70–2.82) | 0.344 |
| Caucasian | 162 (88.5) | 134 (89.9) | 108 (87.1) | 189 (90.4) | |||||
| Gender | Male | 53 (29) | 40 (26.8) | 1.11 (0.69–1.80) | 0.669 | 37 (29.8) | 56 (26.8) | 1.16 (0.71–1.90) | 0.549 |
| Female | 130 (71) | 109 (73.2) | 87 (70.2) | 153 (73.2) | |||||
| Age | Years | 54.4 (11.2) | 50.5 (10.2) | NA | 0.001a | 52.3 (10.9) | 53.3 (11.1) | NA | 0.434 |
| Fisher grade | 2 | 39 (21.3) | 68 (45.9) | NA | <0.001a | 26 (21) | 81 (38.9) | NA | <0.001a |
| 3 | 98 (53.6) | 71 (48) | 67 (54) | 102 (49) | |||||
| 4 | 46 (25.1) | 9 (6.1) | 31 (25) | 25 (12) |
| Covariate | Group | MRS3 (3–6) N (%) | MRS3 (0–2) N (%) | OR (95% CI) | P value | MRS12 (3–6) N (%) | MRS12 (0–2) N (%) | OR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|---|
| Race | Non-Caucasian | 14 (17.7) | 10 (5.8) | 3.51 (1.48–8.30) | 0.003a | 8 (11.8) | 12 (6.8) | 1.83 (0.71–4.70) | 0.202 |
| Caucasian | 65 (82.3) | 163 (94.2) | 60 (88.2) | 165 (93.2) | |||||
| Gender | Male | 24 (30.4) | 47 (27.2) | 1.17 (0.65–2.10) | 0.599 | 16 (23.5) | 50 (28.2) | 0.78 (0.41–1.50) | 0.456 |
| Female | 55 (69.6) | 126 (72.8) | 52 (76.5) | 127 (71.8) | |||||
| Age | Years | 53.0 (10.9) | 55.0 (10.9) | NA | 0.175 | 53.9 (11.1) | 55.5 (11.6) | NA | 0.326 |
| Hunt and Hess | Favorable (0–2) | 17 (21.5) | 94 (54.3) | 4.34 (2.35–8.02) | <0.001a | 13 (19.1) | 96 (54.2) | 5.01 (2.56–9.83) | <0.001a |
| Unfavorable (3–5) | 62 (78.5) | 79 (45.7) | 55 (80.9) | 81 (45.8) |
CI, confidence interval; CND, clinical neurologic deterioration; DCI, delayed cerebral ischemia; MRS, Modified Rankin Scale score at 3 and 12 months: Unfavorable (3 to 6), Favorable (0 to 2); OR, odds ratio.
a
Statistical significance established at P<0.05.